EVALUATION OF THE EFFECTS OF ULTRA-LOW DOSE NALOXONE ON BRACHIAL PLEXUS BLOCK WITH BUPIVACAINE

Amit Sharma Bhattarai¹, Gentle Sunder Shrestha², Megha Koirala³, Pramesh Sunder Shrestha⁴, Moda Nath Marhatta¹

ABSTRACT

Introduction
Adjuvants are used in conjunction with local anaesthetics for brachial plexus block to quicken onset, prolong duration and augment the quality of anaesthesia.

Objectives
The study aims to evaluate the effect of adding ultra-low dose naloxone to bupivacaine on the duration of postoperative analgesia.

Methodology
A prospective, randomized, double-blind study was conducted including forty American Society of Anesthesiologists Physical Status (ASA PS) I and II patients of either sex between 15 and 65 years of age scheduled for upper limb surgery. They were randomized into two groups. Group BN received a mixture of 0.33% plain bupivacaine with ultra-low dose naloxone (100 ng) and group BS received 0.33% plain bupivacaine with saline. The procedure was standardized in both groups. The onset of sensory and motor block were assessed with pinprick sensation and muscle power respectively. Visual Analogue Score (VAS) was used to assess the pain at 1, 2, 4, 8 and 12 hours postoperatively.

Result
The patients were comparable with respect to age, sex, ASA PS, baseline hemodynamic and respiratory parameters and duration of surgery. The mean duration of analgesia in group BN was significantly longer (610.7±125.4 mins) as compared to group BS (354.3±59.6 mins) (p<0.001). No complications were noted in both the groups.

Conclusion
This study demonstrated that 100 ng naloxone, when used with 0.33% plain bupivacaine for supraclavicular brachial plexus block, prolongs postoperative analgesia significantly after upper limb surgeries, without any significant side effects.

KEYWORD
Bupivacaine, naloxone, supraclavicular brachial plexus block, ultra-low dose.
INTRODUCTION

Pain is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (definition recommended by the International Association for the Study of Pain (IASP) subcommittee on taxonomy). Prolonged pain may increase postsurgical morbidity and lead to chronic pain syndromes. In pain pathway, the regional block targets the signal traffic to the dorsal horn.

A brachial plexus block provides a useful option as an alternative to general anaesthesia in selected cases where it is possible for upper limb surgeries. The block produces a complete muscle paralysis, sympathetic block and stable hemodynamics. The sympathetic block is responsible to decrease postoperative pain, vasoconstriction and edema. Any adjunct to brachial plexus block should ideally prolong analgesia without systemic effects or prolonged motor block, and reduce the dose of local anaesthetic. Many adjuncts have been evaluated from time to time with various results, most of them being inconclusive. In addition to this, regional anaesthesia is considered to be safer option for the patients in terms of exposure of anaesthetic drugs and airway instrumentation, which can alter the hemodynamics significantly. Also, effective postoperative pain control can significantly reduce the morbidity of the patients and also affect the overall outcome. For this reason, effective postoperative analgesia is considered as a prerequisite to enhance recovery and decrease morbidity. There has been many studies to evaluate the efficacy of adjuvants like morphine, fentanyl, midazolam, clonidine and tramadol in regional block. Naloxone has been used in ultra-low dose in brachial plexus block, and reduce the dose of local anaesthetics.

In this study, we evaluated the effects of the ultra-low dose of naloxone on brachial plexus block along with local anaesthetic agent bupivacaine. The primary outcome was duration of analgesia and the secondary outcomes were onset and duration of block and comparison of adverse effects between two groups.

METHODOLOGY

Ethical approval was obtained from the Institutional Review Board of the Research Department of Institute of Medicine, Kathmandu, Nepal. All the eligible patients were evaluated prior to surgery. We included patients aged 15 to 65 years, of either sex, ASA PS I and II, weighing more than 30 kg, presenting for surgeries at or distal to elbow, and with duration of surgery up to 3 hours. Patients who refused brachial plexus block, were not willing to undergo surgery under brachial plexus block, uncooperative, had addiction to opioids, benzodiazepines and cocaine, with history of hepatic or renal impairment, pregnant women, those who received opioids within 24 hours of surgery, hypersensitivity to the study drugs and with coagulopathy were excluded from the study. For sampling, consecutive sampling method was used, where consecutive eligible patients were enrolled over the six months duration from 1 January to 30 June 2012, and were randomized into two groups. Written informed consent was obtained from 40 patients who were planned for surgeries around and below elbow joint. They were randomized into two groups by computer generated random numbers and blinding was done by Sequentially Numbered, Opaque, Sealed Envelope technique. The patients received either 29 ml of 0.33% plain bupivacaine with 1 ml normal saline (group BS) or 29 ml of 0.33% plain bupivacaine with 1 ml (100 ng) of naloxone (group BN). Study drugs were prepared by anaesthetic assistants not involved in patient care. Both the principal investigator and patients were blinded to the study drugs. After arrival in the operating theatre, standard monitors were attached for measurement of vital signs as per ASA standard (electrocardiogram, non-invasive blood pressure and pulse oximeter). Intravenous access was established and inj. Midazolam 1 mg was administered before performing the block. Patients were kept in supine position for performance of supraclavicular brachial plexus block with head turned to contralateral side and the ipsilateral arm adducted and extended along the side towards the ipsilateral knee as far as possible. To determine the point of entry of the needle, the combination of landmarks including midpoint of clavicle, interscalene groove and subclavian artery were identified. The point of entry was 1.5-2 cm posterior to mid-point of clavicle along the interscalene groove and palpating subclavian artery laterally. Aa 22 G, 2-inch blunt bevelled nerve stimulator needle (Stimuplex® B Braun) was used to localise the brachial plexus. The stimulating frequency was set at 2 Hz, the duration of stimulus 0.1 millisecond and intensity of stimulating current starting at 3 mA and gradually decreased. In case of pain due to fractures, the initial current was rapidly decreased to a comfortable level. The position of the needle was considered acceptable and appropriate when a stimulating current of 0.5 mA or less elicited as light distal motor response. The prepared solution was injected in 5 ml aliquots following aspiration to rule out intravascular injection. Intercostobrachial nerve blockade was performed by depositing 5 ml of 1% lidocaine subcutaneously, superiorly and inferiorly along axillary crease with a different syringe to avoid tourniquet pain, if applied.

The sensory block was assessed with pinprick sensation with an atraumatic needle tip along the distribution of median, ulnar and radial nerves and compared in same areas on contralateral side. Similarly, motor block was assessed for the four nerves (musculocutaneous, radial, median and ulnar) by evaluating patient’s ability to extend or flex elbow, wrist, hand or fingers and by comparing with the other side. Sensory block grading was done as grade...
There were no complications noted in either group.

The onset of acceptable sensory, motor and complete block in group BS was 354.3±59.6 minutes (p<0.001). (Table 2).

The patients’ age, sex, weight, ASA physical status and duration of surgery were comparable in both groups (Table 1). Onset of acceptable sensory, motor and complete block were also comparable in both groups (Table 2). The mean duration of sensory block (analgesia) in group BN was 610.7±125.4 minutes and the mean duration of sensory block in group BS was 354.3±59.6 minutes (p<0.001). (Table 2). There were no complications noted in either group.

### RESULTS

The data were collected in preformed data collection sheet. The statistical analysis of the data was done by using SPSS software version 17. Independent t-test, Mann-Whitney U test, Wilcoxon test and Chi square test were used for analysis of all variables of interest. P value of less than 0.05 was considered statistically significant.

### DISCUSSION

Till date, there are only a few studies exploring the effects of naloxone on peripheral nerve blockade or epidural analgesia. Ultra-low dose naloxone has been shown to enhance antinociceptive effects of morphine when used via intravenous route. It has also been used in patient-controlled analgesia (PCA) safely to enhance the potency of opioids and reduce their side effects. Our study was conducted to assess and compare the duration of analgesia in supracricular brachial plexus block with 0.33% plain bupivacaine with ultra-low dose of naloxone (100 ng) as an adjuvant and to assess the onset of block and any side effects. The ultra-low dose naloxone pertains to a dosing range when less than 1 µg quantities of drug are used. In our study, we have used 100 ng of naloxone as an adjuvant to brachial plexus block.

Our study showed that addition of an ultra-low dose (100 ng) of naloxone as an adjuvant to 29 ml of 0.33% plain bupivacaine significantly prolonged the duration of analgesia as compared to plain bupivacaine 0.33% alone. However, the median onset time were same in both groups. These findings are comparable to a study done by Movafegh A et al, where 100 ng of naloxone was added to 34 ml 1.5% lidocaine and 2 ml 0.9% sodium chloride for brachial plexus block in the patients scheduled to undergo elective forearm surgery under axillary brachial plexus block. They found significantly prolonged duration of time to first postoperative pain (67±7 mins in lidocaine group vs 92±10 mins in ultra-low dose naloxone group, P<0.001).

The mechanism of analgesic action of ultra-low dose naloxone is very less known. There are few proposed mechanisms by which it works, like the release of endorphins or displacement of endorphins from their binding site. It is also thought to selectively block the excitatory effects of opioids without decreasing the analgesic potency. The ultra-low dose used in various studies have shown to displace ligands from their binding sites and enhance the release of endorphins which is thought to be responsible for the analgesic effects demonstrated in these studies. Similarly it may exert a paradoxical effect of analgesia by enhanced release of opioid as well as upregulation of opioid receptors. Also, it may exert a paradoxical effect of analgesia by enhanced release of opioid as well as upregulation of opioid receptors. On the molecular level, it may prevent a G protein coupling switch (Gi/o to Gs) of the mu opioid receptor that occurs briefly after acute or persistently after chronic administration of opioids. Apart from all these effects, it may also exert some anti-pronociceptive effect. The safety of ultra-low dose naloxone in brachial plexus block has already been established. Naloxone in various doses has been safely used via intravenous and epidural route as an adjunct to analgesia and to reduce the side effects of opioids. The dose-responsiveness of naloxone has been validated by different studies. These studies have investigated the optimal dose of naloxone additive used as an adjunct to analgesia. Based on the studies, the optimal dose of 100 nanogram would represent...
the standard dose to be used as an adjuvant in brachial plexus block. Low dose of naloxone have been shown to displace the endogenous ligands from receptor sites or release endorphins and it is possible that they exert an analgesic effect. In a study done with ultralow dose of naloxone added to ropivacaine as an adjuvant in femoral nerve block, the results showed that there was significant prolongation of postoperative analgesia without any effect on onset of sensory blockade, satisfaction and complications. While the opioid antagonists can cause both analgesia and hyperalgesia based on dose used, with smaller doses causing paradoxical analgesia and larger doses causing hyperalgesia in animal models, an ultra-low dose of naloxone in clinical setting has enhanced the analgesic effects of morphine. In our study, however, we used a fixed and single dose of naloxone. Future studies with other doses of naloxone to prove its efficacy can be reasonable as the ultra-low dose ranges from any dosing below one microgram. Also, further studies need to be done to compare naloxone with other adjuvants like clonidine and along with other local anaesthetic agents to compare the analgesic efficacy between the drugs.

CONCLUSION
In conclusion, our study has demonstrated that an ultra-low dose of naloxone (100 ng), when used with 0.33% plain bupivacaine in supraclavicular brachial plexus block significantly prolongs the duration of postoperative analgesia after upper limb surgeries at or distal to elbow, without any significant side effects.

LIMITATIONS OF THE STUDY
The major limitation of the study is that it was a single center study conducted within a limited span of time, because of which the sample size was small. It however does provide a framework for further larger multicentric studies. Besides this, only one dose of naloxone was studied. A dose finding study, exploring the effectiveness of various doses could have been imperative.

ACKNOWLEDGEMENT
None.

REFERENCES